Gética 2020

28 VI FORO DE Inmunología Traslacional e INMUNOTERAPIA DEL CÁNCER 10. Horton JD, Knochelmann H, Armeson K, et al. Neoadju- vant presurgical PD-1 inhibition in oral cavity squamous cell carcinoma. J Clin Oncol 2019;37:2574-2574. 11. Lawrence MS, Stojanov P, Polak P, et al. Mutational het- erogeneity in cancer and the search for new cancer-as- sociated genes. Nature 2013;499(7457):214-8. 12. Licitra LF, Haddad RI, Even C, et al. EAGLE: A phase 3, randomized, open-label study of durvalumab (D) with or without tremelimumab (T) in patients (pts) with re- current or metastatic head and neck squamous cell car- cinoma (R/M HNSCC). J Clin Oncol 2019;37:6012-6012. 13. McBride SM, Sherman EJ, Tsai CJ, et al. A phase II ran- domized trial of nivolumab with stereotactic body radiotherapy (SBRT) versus nivolumab alone in met- astatic (M1) head and neck squamous cell carcinoma (HNSCC). J Clin Oncol 2018;36(Suppl.15):6009-6009. DOI: 10.1200/JCO.2018.36.15_suppl.6009. 14. Rizvi NA, Hellmann MD, Snyder A, et al. Cancer immu- nology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 2015;348(6230):124-8. 15. Saada-Bouzid E, Defaucheux C, Karabajakian A, et al. Hy- perprogression during anti-PD-1/PD-L1 therapy in patients with recurrent and/or metastatic head and neck squa- mous cell carcinoma. Ann Oncol 2017;28(7):1605-11. 16. Seiwert TY, Burtness B, Mehra R, et al. Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial. Lancet Oncol 2016;17:956-65. 17. Siu LL, Even C, Mesia R, et al. Safety and Efficacy of Durvalumab With or Without Tremelimumab in Patients With PD-L1-Low/Negative Recurrent or Metastatic HN- SCC: The Phase 2 CONDOR Randomized Clinical Trial. JAMA Oncol 2019;5(2):195-203. 18. Uppaluri R, Zolkind P, Lin T, et al. Neoadjuvant pembroli- zumab in surgically resectable, locally advanced HPV negative head and neck squamous cell carcinoma (HN- SCC). J Clin Oncol 2017;35:6012. 19. Whiteside TL. Immune cells in the tumor microenviron- ment. Mechanisms responsible for functional and sig- naling defects. Adv Exp Med Biol 1998;451:167-71.